Companies ›Healthcare ›4597.T

4597.T — Tokyo Stock Exchange Pharmaceuticals

4597.T

¥23,00

Open in Charts → Attach watcher ⌖

— —

JPY

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

6,3B JPY

P/E

—

EV / Rev

—

Div yield

0,00 %

Op margin

-200,7 %

ROE

-50,0 %

Net margin

-204,2 %

Debt / equity

0,05

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

The company is a pharmaceuticals firm that develops and sells drugs, primarily generating revenue through product sales.

Business. The company is a pharmaceuticals firm that develops and sells drugs, primarily generating revenue through product sales.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-50,0 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 4597.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 4597.T. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

The company is a pharmaceuticals firm that develops and sells drugs, primarily generating revenue through product sales.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

The company has a market price of 25.0 JPY and a market capitalization of 6,825,130,550 JPY, with a price-to-book ratio of 3.9 and a price-to-tangible-book ratio of 3.9. The enterprise value to EBITDA is -6.43, and the enterprise value to revenue is 12.9. The company's liquidity position is strong, with a current ratio of 6.06 and cash and equivalents of 1,387,000,000 JPY.

The company's profitability is negative, with a return on equity of -0.5 and a return on assets of -0.4084. The operating income is -861,000,000 JPY, and the net income is -876,000,000 JPY. The gross profit is 208,000,000 JPY, and the revenue is 429,000,000 JPY. The company's debt-to-equity ratio is 0.05, indicating a low level of leverage.

The company's revenue is concentrated in a single segment, with no disclosed geographic diversification. The operating cash flow is -847,000,000 JPY, and the free cash flow is -839,000,000 JPY. The capital expenditure is 0.0 JPY, indicating no recent investment in physical assets.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The operating income and net income are negative, indicating a decline in profitability. The company's revenue is 429,000,000 JPY, and the operating cash flow is -847,000,000 JPY.

The company's risk assessment indicates low liquidity and dilution risks. The key flags show no immediate filing-based liquidity or dilution flags. The company's debt-to-equity ratio is 0.05, and the current ratio is 6.06, indicating a strong liquidity position.

Recent events include the disclosure of the company's financial performance, with a last actual EPS of -3.69 JPY and a last actual revenue of 429,000,000 JPY. Analysts have set a mean price target of 47.00 JPY, indicating a potential upside from the current market price.

Key takeaways

The company has a strong liquidity position with a current ratio of 6.06 and cash and equivalents of 1,387,000,000 JPY.
The company's profitability is negative, with a return on equity of -0.5 and a return on assets of -0.4084.
The company's revenue is concentrated in a single segment, with no disclosed geographic diversification.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year.
The company's risk assessment indicates low liquidity and dilution risks.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

¥23,00

Market cap

¥6.83B

Enterprise valueⓘ

¥5.53B

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

3.9x

P / Tangible bookⓘ

3.9x

Tangible book

¥1.75B

Net cashⓘ

¥1.29B

Current ratioⓘ

6.1

Debt / equityⓘ

0.1

ROAⓘ

-40.8%

ROEⓘ

-50.0%

Cash conversionⓘ

97.0%

CapEx / revenueⓘ

0.0%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

12-month price target¥47,00 · Median ¥47,00

Low ¥47,00High ¥47,00

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low¥47,00

Mean¥47,00

Median¥47,00

High¥47,00

Spot¥23,00

+104.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-200,7 %Bottom quartile

Net Margin-204,2 %Bottom quartile

ROE-50,0 %Bottom quartile

Capex / Rev0,0 %Above P75

D/E0,05Above median

Cash Conv0,97Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue

Source documents

4597.T Market data — financials · 2026-05-26
Solasia Pharma KK Market data — analyst estimates · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

4597.TCanonical

Tokyo Stock Exchange · JPY

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread